NASDAQ:TGTX - TG Therapeutics Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $64.00
Forecasted Upside: 64.91 %
Number of Analysts: 5
Breakdown:
0 Sell Ratings
1 Hold Ratings
4 Buy Ratings
0 Strong Buy Ratings

^$38.81 As of 06/24/2021 01:00 AM ET

▲ +0.9 (2.37%)

1 month | 3 months | 12 months

Get New TG Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for TGTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TGTX

^$64.00

▲ +64.91% Upside Potential

This price target is based on 5 analysts offering 12 month price targets for TG Therapeutics in the last 3 months. The average price target is $64.00, with a high forecast of $95.00 and a low forecast of $38.00. The average price target represents a 64.91% upside from the last price of $38.81.

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in TG Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/1/2020

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/31/2020

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/29/2020

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/27/2020

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/26/2020

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/26/2021

0 strong buy ratings
5 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

5/25/2021

0 strong buy ratings
4 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

6/24/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/20/2021	The Goldman Sachs Group	Initiated Coverage	Neutral	$50.00	High
4/19/2021	HC Wainwright	Boost Price Target	Buy	$79.00 ➝ $89.00	High
2/8/2021	HC Wainwright	Boost Price Target	Buy	$78.00 ➝ $79.00	Medium
2/5/2021	B. Riley	Boost Price Target	Buy	$90.00 ➝ $95.00	High
1/19/2021	HC Wainwright	Boost Price Target	Buy	$61.00 ➝ $78.00	Low
12/10/2020	HC Wainwright	Boost Price Target	Buy	$38.00 ➝ $61.00	High
10/28/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$30.00 ➝ $48.00	Low
9/1/2020	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$38.00	High
8/11/2020	HC Wainwright	Boost Price Target	Buy	$32.00 ➝ $38.00	Medium
8/10/2020	B. Riley	Reiterated Rating	Buy	$37.00	Medium
6/15/2020	B. Riley	Reiterated Rating	Buy	$37.00	Low
6/5/2020	Evercore ISI	Initiated Coverage	Outperform	$60.00	High
6/1/2020	B. Riley	Reiterated Rating	Buy	$37.00	High
5/29/2020	HC Wainwright	Reiterated Rating	Buy		High
5/18/2020	HC Wainwright	Reiterated Rating	Buy	$32.00	Medium
5/17/2020	B. Riley	Boost Price Target	Buy	$29.00 ➝ $37.00	Medium
5/12/2020	HC Wainwright	Reiterated Rating	Buy	$32.00	Medium
5/6/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$19.00 ➝ $35.00	High
5/6/2020	B. Riley	Boost Price Target	Buy	$25.00 ➝ $29.00	High
5/5/2020	HC Wainwright	Boost Price Target	Buy	$24.00 ➝ $32.00	High
4/17/2020	B. Riley	Reiterated Rating	Buy	$25.00	High
1/17/2020	HC Wainwright	Boost Price Target	Buy	$20.00 ➝ $24.00	High
12/10/2019	HC Wainwright	Reiterated Rating	Buy	$20.00	High
11/27/2019	B. Riley	Initiated Coverage	Buy	$12.00	High
11/12/2019	HC Wainwright	Reiterated Rating	Buy	$20.00	Medium
10/28/2019	HC Wainwright	Reiterated Rating	Buy	$20.00	Medium
6/11/2019	B. Riley	Reiterated Rating	Buy		Medium
5/13/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$17.00	High
4/12/2019	HC Wainwright	Reiterated Rating	Buy	$20.00	Low
3/29/2019	Cantor Fitzgerald	Initiated Coverage	Overweight	$17.00	High
2/6/2019	Jefferies Financial Group	Reiterated Rating	Buy	$8.00	High
1/22/2019	HC Wainwright	Reiterated Rating	Buy		High
1/8/2019	B. Riley	Initiated Coverage	Buy	$10.00	Low
11/12/2018	HC Wainwright	Reiterated Rating	Buy	$20.00	High
11/2/2018	HC Wainwright	Reiterated Rating	Buy	$21.00	Medium
9/26/2018	LADENBURG THALM/SH SH	Set Price Target	Buy	$27.00	N/A
9/25/2018	Raymond James	Downgrade	Strong-Buy ➝ Outperform	$22.00 ➝ $12.00	High
8/7/2018	HC Wainwright	Reiterated Rating	Buy	$38.00	High
4/25/2018	Raymond James	Reiterated Rating	Buy		Low
4/19/2018	Raymond James	Reiterated Rating	Buy		Low
3/9/2018	B. Riley	Reiterated Rating	Buy ➝ Buy	$21.50 ➝ $27.00	Medium
1/17/2018	B. Riley	Reiterated Rating	Buy	$21.50	Low
1/16/2018	HC Wainwright	Reiterated Rating	Buy	$33.00	Low
1/8/2018	HC Wainwright	Reiterated Rating	Buy	$33.00	Low
12/12/2017	Raymond James	Reiterated Rating	Buy		Low
12/11/2017	HC Wainwright	Reiterated Rating	Buy	$33.00	High
12/11/2017	B. Riley	Reiterated Rating	Buy	$21.50	High
12/1/2017	B. Riley	Initiated Coverage	Buy ➝ Buy	$21.50	High
11/14/2017	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $33.00	N/A
10/3/2017	SunTrust Banks	Reiterated Rating	Buy	$28.00	Medium
6/17/2017	(FBRC)	Reiterated Rating	Buy		Low
6/5/2017	Jefferies Financial Group	Reiterated Rating	Buy	$23.00	Medium
5/18/2017	(FBRC)	Reiterated Rating	Buy		Low
5/1/2017	(FBRC)	Reiterated Rating	Buy		Low
4/25/2017	Jefferies Financial Group	Initiated Coverage	Buy ➝ Buy	$23.00	High
4/21/2017	Raymond James	Reiterated Rating	Buy		High
3/13/2017	SunTrust Banks	Set Price Target	Buy	$28.00	Low
3/8/2017	LADENBURG THALM/SH SH	Set Price Target	Buy	$30.00	Low
3/7/2017	HC Wainwright	Reiterated Rating	Buy	$18.00	N/A
3/7/2017	Langenberg & Company	Boost Price Target	Positive	$28.00 ➝ $30.00	N/A
3/6/2017	(FBRC)	Reiterated Rating	Outperform ➝ Outperform	$24.00 ➝ $26.00	N/A
2/22/2017	Aegis	Initiated Coverage	Buy	$26.00	N/A
12/7/2016	Roth Capital	Set Price Target	Buy	$33.00	N/A
12/6/2016	(FBRC)	Set Price Target	Buy	$24.00	N/A
11/8/2016	Roth Capital	Reiterated Rating	Buy	$33.00	N/A
10/27/2016	Roth Capital	Set Price Target	Buy	$33.00	N/A
10/20/2016	Roth Capital	Set Price Target	Buy	$33.00	N/A
10/15/2016	HC Wainwright	Reiterated Rating	Buy	$22.00 ➝ $18.00	N/A
10/15/2016	LADENBURG THALM/SH SH	Reiterated Rating	Buy	$28.00	N/A
10/14/2016	Roth Capital	Reiterated Rating	Buy	$33.00	N/A
10/6/2016	Brean Capital	Reiterated Rating	Buy	$28.00	N/A
9/19/2016	(FBRC)	Reiterated Rating	Buy		N/A
8/24/2016	S&P Equity Research	Lower Price Target		$7.15 ➝ $6.40	N/A
8/10/2016	Roth Capital	Reiterated Rating	Buy	$33.00	N/A

(Data available from 6/24/2016 forward)

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. The company is headquartered in New York, New York.

Today's Range

Now: $38.81

$37.99

$38.84

50 Day Range

MA: $37.86

$32.50

$44.78

52 Week Range

Now: $38.81

$17.67

$56.74

Volume

842,938 shs

Average Volume

1,440,961 shs

Market Capitalization

$5.49 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.16

Frequently Asked Questions

What sell-side analysts currently cover shares of TG Therapeutics?

The following Wall Street sell-side analysts have issued reports on TG Therapeutics in the last year: B. Riley, Cantor Fitzgerald, HC Wainwright, JPMorgan Chase & Co., The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for TGTX.

What is the current price target for TG Therapeutics?

5 Wall Street analysts have set twelve-month price targets for TG Therapeutics in the last year. Their average twelve-month price target is $64.00, suggesting a possible upside of 65.6%. B. Riley has the highest price target set, predicting TGTX will reach $95.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $38.00 for TG Therapeutics in the next year.
View the latest price targets for TGTX.

What is the current consensus analyst rating for TG Therapeutics?

TG Therapeutics currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TGTX will outperform the market and that investors should add to their positions of TG Therapeutics.
View the latest ratings for TGTX.

What other companies compete with TG Therapeutics?

Other companies that are similar to TG Therapeutics include Horizon Therapeutics Public, Alnylam Pharmaceuticals, UCB, Catalent, Viatris, Elanco Animal Health, Zai Lab, BioMarin Pharmaceutical, Grifols, Dr. Reddy's Laboratories, Teva Pharmaceutical Industries, Ono Pharmaceutical, Maravai LifeSciences, CureVac and Bausch Health Companies.

How do I contact TG Therapeutics' investor relations team?

TG Therapeutics' physical mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company's listed phone number is 212-554-4484 and its investor relations email address is [email protected] The official website for TG Therapeutics is www.tgtherapeutics.com.